Search Results for "Rituximab Patent"

20:53 EDT 27th May 2017 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...


India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Rituximab Treatment in Neuromyelitis Optica Spectrum Disorders

Based on a meta-analysis and review of rituximab use in the treatment of neuromyelitis optica spectrum disorders, the authors reported that rituximab was efficacious in reducing relapse rate and disab...

Rituximab biosimilar granted EU marketing authorisation

The European Commission has approved Truxima, a rituximab biosimilar, for all indications of reference rituximab in the European Union (EU). Truxima is a mAb that targets CD20, a protein found on t...

Rituximab in the Treatment of Inflammatory Myopathies

Get up-to-date on what there is to know about the use of rituximab therapy in the management of myositis. Rheumatology

Subcutaneous Rituximab May Soon Be Approved for Certain Blood Cancers

A new study is suggesting that intravenous and subcutaneous rituximab share similar efficacy and safety profiles.

Rituximab is not effective for the treatment of fatigue in primary biliary cholangitis

Results from the RITPBC trial demonstrated that rituximab was not effective for treatment of fatigue in unselected patients with primary biliary cholangitis (PBC). The study, presented at The Internat...

EMA approval for rituximab biosimilar Truxima

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 16 December 2016 that it had recommended granting of marketing authorization for a rituximab ...

BRIEF-OBJ announces Japanese patent office grants skin delivery patent

* Received notice from patent attorney that japanese patent office has issued deed of letters patent for granting of magnetic microarray patent Source text for Eikon: Further company coverage:

Venetoclax Plus Rituximab: 'Unprecedented' Efficacy in CLL

A new chemo-free combination, venetoclax and rituximab, has shown complete response rates in half of patients with refractory or relapsed chronic lymphocytic leukemia (CLL). Medscape Medical News

Matching PubMed Articles

Patent highlights June-July 2016.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Rituximab-induced lung disease.

Pulmonary toxicity is a rare complication of Rituximab therapy. Although Rituximab is relatively safe and can be administered in an outpatient setting, Rituximab-associated lung disease has been repor...

A novel classification method for aid decision of traditional Chinese patent medicines for stroke treatment.

Traditional Chinese patent medicines are widely used to treat stroke because it has good efficacy in the clinical environment. However, because of the lack of knowledge on traditional Chinese patent m...

Rituximab: Uses in Dermatology.

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two o...

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.

The addition of rituximab to standard chemotherapy has significantly improved survival in patients with lymphoma. Recently, maintenance therapy with rituximab has been shown to prevent relapse and pro...

Search Whole site using Google

Quick Search
Advertisement Advertisement